Seizert Capital Partners LLC Has $6.68 Million Stake in Amgen Inc. $AMGN

20 Jan 2026, 10:22 by Renee Jackson · The Cerbat Gem

Seizert Capital Partners LLC trimmed its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 85.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,678 shares of the medical research company’s stock after selling 139,258 shares during the period. Seizert Capital Partners LLC’s holdings in Amgen were worth $6,682,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Sequoia Financial Advisors LLC grew its holdings in Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after purchasing an additional 3,619 shares during the period. OLD National Bancorp IN raised its stake in Amgen by 296.2% in the 2nd quarter. OLD National Bancorp IN now owns 18,004 shares of the medical research company’s stock valued at $5,027,000 after acquiring an additional 13,460 shares during the period. Atlantic Union Bankshares Corp raised its holdings in Amgen by 165.0% in the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after acquiring an additional 6,627 shares during the period. D.A. Davidson & CO. increased its position in Amgen by 2.6% during the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after acquiring an additional 6,222 shares during the period. Finally, Davis Capital Management acquired a new stake in shares of Amgen during the 3rd quarter worth $1,841,000. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN opened at $324.14 on Tuesday. The firm has a market cap of $174.54 billion, a PE ratio of 25.17, a P/E/G ratio of 2.94 and a beta of 0.45. The stock has a 50-day moving average price of $331.69 and a 200-day moving average price of $306.41. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $346.38. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company’s revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is 73.57%.

Analyst Ratings Changes

A number of research firms recently commented on AMGN. BMO Capital Markets lifted their price objective on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Morgan Stanley dropped their price objective on Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Argus lifted their price objective on shares of Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a research report on Tuesday, December 30th. Piper Sandler lifted their price objective on Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Finally, UBS Group raised Amgen to a “strong-buy” rating in a report on Wednesday, January 7th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $339.45.

Check Out Our Latest Analysis on AMGN

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 10,908 shares of company stock worth $3,674,966. 0.69% of the stock is currently owned by company insiders.

Amgen Company Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.